(VIANEWS) – MakeMyTrip Limited (MMYT), Neurocrine Biosciences (NBIX), Goldman Sachs Group (GS) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. MakeMyTrip Limited (MMYT)
29.7% sales growth and 5.58% return on equity
MakeMyTrip Limited, an online travel company, sells travel products and solutions in India, the United States, Singapore, Malaysia, Thailand, the United Arab Emirates, Peru, Colombia, and Indonesia. The company operates through three segments: Air Ticketing, Hotels and Packages, and Bus Ticketing. Its services and products include air tickets; hotels; packages; rail tickets; bus tickets; and car hire, as well as ancillary travel requirements, such as visa processing and facilitating access to travel insurance. The company allows travelers to research, plan, book, and purchase travel services and products through its Websites makemytrip.com, goibibo.com, redbus.in, makemytrip.com.sg, and makemytrip.ae; and other technology-enhanced distribution channels, such as call centers, travel stores, and travel agents' network, as well as mobile service platform. As of March 31, 2021, it had approximately 150 franchisee-owned travel stores. The company serves leisure and corporate travelers. MakeMyTrip Limited was incorporated in 2000 and is based in Gurugram, India.
Earnings Per Share
As for profitability, MakeMyTrip Limited has a trailing twelve months EPS of $0.46.
PE Ratio
MakeMyTrip Limited has a trailing twelve months price to earnings ratio of 131.41. Meaning, the purchaser of the share is investing $131.41 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.58%.
Yearly Top and Bottom Value
MakeMyTrip Limited’s stock is valued at $60.45 at 06:22 EST, below its 52-week high of $63.79 and way higher than its 52-week low of $22.50.
Earnings Before Interest, Taxes, Depreciation, and Amortization
MakeMyTrip Limited’s EBITDA is 8.56.
Sales Growth
MakeMyTrip Limited’s sales growth is 37.6% for the present quarter and 29.7% for the next.
Moving Average
MakeMyTrip Limited’s value is way higher than its 50-day moving average of $53.03 and way above its 200-day moving average of $40.21.
2. Neurocrine Biosciences (NBIX)
22.1% sales growth and 12.68% return on equity
Neurocrine Biosciences, Inc., a neuroscience-focused biopharmaceutical company, discovers, develops, and delivers various treatments for people with neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products also include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; NBI-827104 to treat rare pediatric epilepsy and other indications; and crinecerfont. The company's products in clinical development also comprise NBI-1065844 for the treatment of negative symptoms of schizophrenia; NBI-1065845 for the treatment of resistant depression; and NBI-1065846 for treating anhedonia in depression. It has license and collaboration agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Neurocrine Biosciences has a trailing twelve months EPS of $2.47.
PE Ratio
Neurocrine Biosciences has a trailing twelve months price to earnings ratio of 53.98. Meaning, the purchaser of the share is investing $53.98 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.68%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 25%, now sitting on 1.89B for the twelve trailing months.
3. Goldman Sachs Group (GS)
14% sales growth and 7.24% return on equity
The Goldman Sachs Group, Inc., a financial institution, provides a range of financial services for corporations, financial institutions, governments, and individuals worldwide. It operates through Global Banking & Markets, Asset & Wealth Management, and Platform Solutions segments. The Global Banking & Markets segment provides financial advisory services, including strategic advisory assignments related to mergers and acquisitions, divestitures, corporate defense activities, restructurings, and spin-offs; and relationship lending, and acquisition financing, as well as secured lending, through structured credit and asset-backed lending and involved in financing under securities to resale agreements. This segment also offers client execution activities for cash and derivative instruments; credit and interest rate products; and provision of mortgages, currencies, commodities, and equities related products, as well as underwriting services. The Asset & Wealth Management segment manages assets across various classes, including equity, fixed income, hedge funds, credit funds, private equity, real estate, currencies, and commodities; and provides customized investment advisory solutions, wealth advisory services, personalized financial planning, and private banking services, as well as invests in corporate equity, credit, real estate, and infrastructure assets. The Platform Solutions segment offers credit cards and point-of-sale financing for purchase of goods or services. This segment also provides cash management services, such as deposit-taking and payment solutions for corporate and institutional clients. The Goldman Sachs Group, Inc. was founded in 1869 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Goldman Sachs Group has a trailing twelve months EPS of $22.88.
PE Ratio
Goldman Sachs Group has a trailing twelve months price to earnings ratio of 17.78. Meaning, the purchaser of the share is investing $17.78 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.24%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 0.5% and 166.6%, respectively.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Feb 28, 2024, the estimated forward annual dividend rate is 11 and the estimated forward annual dividend yield is 2.84%.
Yearly Top and Bottom Value
Goldman Sachs Group’s stock is valued at $406.82 at 06:22 EST, above its 52-week high of $397.49.
Moving Average
Goldman Sachs Group’s worth is higher than its 50-day moving average of $385.04 and way higher than its 200-day moving average of $344.97.
4. Amazon (AMZN)
11.8% sales growth and 17.49% return on equity
Amazon.com, Inc. engages in the retail sale of consumer products, advertising, and subscriptions service through online and physical stores in North America and internationally. The company operates through three segments: North America, International, and Amazon Web Services (AWS). It also manufactures and sells electronic devices, including Kindle, Fire tablets, Fire TVs, Echo, Ring, Blink, and eero; and develops and produces media content. In addition, the company offers programs that enable sellers to sell their products in its stores; and programs that allow authors, independent publishers, musicians, filmmakers, Twitch streamers, skill and app developers, and others to publish and sell content. Further, it provides compute, storage, database, analytics, machine learning, and other services, as well as advertising services through programs, such as sponsored ads, display, and video advertising. Additionally, the company offers Amazon Prime, a membership program. The company's products offered through its stores include merchandise and content purchased for resale and products offered by third-party sellers. It serves consumers, sellers, developers, enterprises, content creators, advertisers, and employees. Amazon.com, Inc. was incorporated in 1994 and is headquartered in Seattle, Washington.
Earnings Per Share
As for profitability, Amazon has a trailing twelve months EPS of $2.9.
PE Ratio
Amazon has a trailing twelve months price to earnings ratio of 61.68. Meaning, the purchaser of the share is investing $61.68 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.49%.
Volume
Today’s last reported volume for Amazon is 24792600 which is 44.17% below its average volume of 44414600.
Previous days news about Amazon(AMZN)
- According to Zacks on Friday, 22 March, "Some better-ranked stocks from the broader technology sector are BlackLine (BL Quick QuoteBL – Free Report) , Amazon (AMZN Quick QuoteAMZN – Free Report) and Dell Technologies (DELL Quick QuoteDELL – Free Report) , each carrying a Zacks Rank #2 (Buy) at present. "
- According to CNBC on Friday, 22 March, "The potential buyers of FTX’s shares comprise a syndicate of new investors for Anthropic, a source said, meaning Amazon and Alphabet would not be involved. "
- According to Zacks on Thursday, 21 March, "Alphabet, which currently carries a Zacks Rank #3 (Hold), has intensified the healthcare battle with its above-mentioned efforts for its peers like Amazon (AMZN Quick QuoteAMZN – Free Report) , Microsoft (MSFT Quick QuoteMSFT – Free Report) and Oracle (ORCL Quick QuoteORCL – Free Report) , which are also making concerted efforts to expand their footprints in the promising healthcare space.", "In this regard, Amazon’s extended collaboration with Philips to improve digital workflow integration and AI/ML capabilities in pathology labs and healthcare organizations with the support of its cloud computing platform, Amazon Web Services, remains noteworthy."
5. Bruker Corporation (BRKR)
11.7% sales growth and 33.67% return on equity
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Earnings Per Share
As for profitability, Bruker Corporation has a trailing twelve months EPS of $2.9.
PE Ratio
Bruker Corporation has a trailing twelve months price to earnings ratio of 32.51. Meaning, the purchaser of the share is investing $32.51 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 33.67%.
Volume
Today’s last reported volume for Bruker Corporation is 409249 which is 50.37% below its average volume of 824640.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is a negative 28.1% and positive 14% for the next.
Yearly Top and Bottom Value
Bruker Corporation’s stock is valued at $94.27 at 06:22 EST, under its 52-week high of $94.86 and way higher than its 52-week low of $53.79.
Moving Average
Bruker Corporation’s worth is way higher than its 50-day moving average of $80.29 and way higher than its 200-day moving average of $70.27.
6. JD.com (JD)
10.9% sales growth and 8.15% return on equity
JD.com, Inc. provides supply chain-based technologies and services in the People's Republic of China. The company offers computers, communication, and consumer electronics products, as well as home appliances; and general merchandise products comprising food, beverage and fresh produce, baby and maternity products, furniture and household goods, cosmetics and other personal care items, pharmaceutical and healthcare products, industrial products, books, automobile accessories, apparel and footwear, bags, and jewelry. It also provides online marketplace services for third-party merchants; marketing services; and omni-channel solutions to customers and offline retailers, as well as online healthcare services. In addition, the company develops, owns, and manages its logistics facilities and other real estate properties to support third parties; offers asset management services for logistics property investors and the sale of development properties; and engages in online retail business. Further, it provides integrated data, technology, business, and user management industry solutions to support the digitization of enterprises and institutions. The company was formerly known as 360buy Jingdong Inc. and changed its name to JD.com, Inc. in January 2014. JD.com, Inc. was incorporated in 2006 and is headquartered in Beijing, the People's Republic of China.
Earnings Per Share
As for profitability, JD.com has a trailing twelve months EPS of $2.11.
PE Ratio
JD.com has a trailing twelve months price to earnings ratio of 12.56. Meaning, the purchaser of the share is investing $12.56 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.15%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Apr 4, 2024, the estimated forward annual dividend rate is 0.76 and the estimated forward annual dividend yield is 3.07%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is a negative 1.5% and positive 1.3% for the next.
Volume
Today’s last reported volume for JD.com is 13814600 which is 12.34% below its average volume of 15759700.
7. Assurant (AIZ)
6.2% sales growth and 14.22% return on equity
Assurant, Inc., together with its subsidiaries, provides lifestyle and housing solutions that support, protect, and connect consumer purchases in North America, Latin America, Europe, and the Asia Pacific. The company operates through three segments: Global Lifestyle, Global Housing, and Global Preneed. The Global Lifestyle segment provides mobile device protection products and services, and extended service contracts for consumer electronics and appliances, as well as assistance services; vehicle protection and related services; and credit and other insurance services. The Global Housing segment offers lender-placed homeowners insurance, manufactured housing, and flood insurance; and renters insurance and related products, as well as voluntary manufactured housing insurance, homeowners insurance, and other specialty products. The Global Preneed segment provides pre-funded funeral insurance, final need insurance, and related services. The company was formerly known as Fortis, Inc. and changed its name to Assurant, Inc. in February 2004. Assurant, Inc. was founded in 1892 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Assurant has a trailing twelve months EPS of $11.96.
PE Ratio
Assurant has a trailing twelve months price to earnings ratio of 15.15. Meaning, the purchaser of the share is investing $15.15 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.22%.
Moving Average
Assurant’s worth is above its 50-day moving average of $172.96 and way above its 200-day moving average of $152.05.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 40.7% and 3.1%, respectively.
Previous days news about Assurant(AIZ)
- According to Zacks on Thursday, 21 March, "Skyward Specialty sports a Zacks Rank #1 (Strong Buy), and Erie Indemnity and Assurant carry a Zacks Rank #2 (Buy) at present. "
